Protalix BioTherapeutics (PLX) Q2 2026 earnings review
Solid Revenue Growth, But True Operating Costs Masked by Grants
Protalix achieved a profitable Q2 2026 with Net Income of $3.8M, driven by a 27% YoY increase in total revenue to $19.9M. The core engine is Elfabrio sales to partner Chiesi, which continue to ramp up globally. However, the earnings quality requires a closer look. A newly passed R&D law provided a $2.1M grant receivable, artificially lowering reported R&D expenses and inflating operating profit. Meanwhile, bulk ordering by partners continues to create massive quarter-to-quarter revenue swings. With $40.7M in cash, the company has runway for its critical PRX-115 Phase 2 trial, but the underlying cash burn is higher than the headline numbers suggest.
🐂 Bull Case
Total revenue climbed to $53.6M year-to-date. Elfabrio is securing a global footprint, bolstered by an extended U.S. patent out to 2035 and new approvals in markets like South Korea.
With $40.7M in cash and short-term deposits—and no debt—Protalix is fully funded to advance its PRX-115 gout program through the critical Phase 2 RELEASE trial.
🐻 Bear Case
Because Protalix relies on partner Chiesi for distribution, revenue is driven by bulk inventory orders, not immediate end-user prescriptions. This creates massive revenue volatility, making it hard to track actual patient adoption.
Despite a 28% YoY increase in goods revenue, Cost of Revenues outpaced it by jumping 32%. Shifts in product mix and partner pricing are causing gross margins to compress.
⚖️ Verdict: ⚪
Neutral. Elfabrio is clearly gaining ground, and the balance sheet is clean. But extreme revenue lumpiness and optical accounting benefits masking real R&D costs make it difficult to evaluate the true operational run-rate.
Key Themes
Elfabrio Global Expansion
Growth in Elfabrio sales is Accelerating. Revenues from selling goods rose to $19.8M, driven heavily by Chiesi. Furthermore, the USPTO granted a Patent Term Extension adding five years of protection (to November 2035) in the U.S., protecting the long-term revenue tail of pegunigalsidase alfa-iwxj.
PRX-115 Clinical Progression
The Phase 2 RELEASE clinical trial for PRX-115 (PEGylated uricase for uncontrolled gout) continues enrollment as planned. Furthermore, Protalix strengthened its IP moat by securing a new U.S. patent ('Modified Uricase and Uses Thereof'). Success here represents the company's biggest future catalyst.
Brazil Order Resurgence
Sales of Elelyso to Fiocruz in Brazil are Reversing their prior-year slump. After citing a $4.7M decrease in sales to Brazil in Q2 2025, management explicitly cited higher sales to Fiocruz as a primary driver of the $4.4M YoY jump in Q2 2026 goods revenue.
The R&D Savings Illusion
Management reported that R&D expenses fell from $6.0M in Q2 2025 to $4.4M in Q2 2026. This contradicts their prior warnings of 'significant, increasing' expenses required for the PRX-115 Phase 2 trial. The reality: operating costs did increase, but the headline number was artificially slashed by a $2.1M grant receivable recorded under a new R&D law. Excluding this one-time accounting benefit, true R&D spend is actually Accelerating.
Cost of Goods Outpacing Revenue
The core gross margin is Decelerating. Revenues from selling goods increased 28% YoY, but Cost of Revenues surged 32% to $7.8M. Management attributes this to a shift away from Pfizer (due to previous manufacturing issues) and toward Chiesi and Fiocruz. If this mix shift is permanent, gross margins will remain suppressed.
Extreme Partner Order Volatility
Quarterly revenues remain highly erratic. Q1 2026 goods revenue was just $7.4M, jumping to $19.8M in Q2. Because Chiesi and Pfizer dictate their own inventory stocking levels, investors lack real-time visibility into the actual number of patients transitioning to Elfabrio or Elelyso.
Macro Tax Pressures
Macro tax conditions are hurting the bottom line. Taxes on income more than doubled YoY to $1.1M in Q2, primarily due to global intangible low-taxed income (GILTI) rules and capitalization limitations under IRC Section 174. Until legislative relief is finalized, tax drags will remain elevated despite the company's Israeli domicile.
Other KPIs
Operating profitability is Reversing from the prior year, nearly quadrupling from $1.17M in 25Q2. However, $2.1M of this $4.67M profit was generated by an R&D grant receivable rather than core commercial operations.
Down sequentially from $51.8M in 26Q1 (which was bolstered by the $25M Chiesi milestone). The company maintains zero debt, providing a clean runway to execute the PRX-115 Phase 2 trial expected to yield data in H2 2027.
Guidance
Stable. The company reiterated its full-year guidance. At the $80.5M midpoint, this implies massive year-over-year growth compared to FY25 ($52.7M), though this is heavily skewed by the one-time $25M milestone payment already received in Q1.
Stable. Management reiterated expectations for core Elfabrio product sales (excluding milestones). This reflects Chiesi's anticipated bulk ordering volume for the year, confirming steady, albeit lumpy, commercial penetration.
Stable. Reaffirmed guidance for the Gaucher disease treatment, reflecting a baseline expectation that Pfizer and Fiocruz will maintain steady, mature ordering patterns despite temporary manufacturing hiccups at Pfizer.
Key Questions
Real R&D Run Rate
Your reported R&D expense dropped due to a $2.1M grant. Looking forward to H2 2026 and 2027, what is the normalized quarterly cash burn we should model for the PRX-115 Phase 2 trial without these accounting offsets?
Gross Margin Trajectory
Cost of revenues grew faster than goods revenue this quarter due to a mix shift. As Chiesi sales become an increasingly larger piece of the pie, should investors expect a permanently lower structural gross margin profile?
End-User Demand Visibility
With the massive volatility in Chiesi's bulk orders between Q1 and Q2, what qualitative or quantitative metrics can you provide regarding actual patient switches and naive starts to reassure investors that end-user demand is matching inventory fill?